Skip Navigation LinksHome > January 2011 - Volume 4 - Issue 1 > Clinical Trial Alert
Text sizing:
A
A
A
Nephrology Times:
doi: 10.1097/01.NEP.0000394225.63353.10
Clinical Trial Alert

Clinical Trial Alert

Free Access
Back to Top | Article Outline
• Acute Kidney Injury •

NCT01227122

NGAL Predictive Value of Acute Kidney Failure After Cardiac Surgery in Patients with Preoperative Chronic Kidney Failure

Ages eligible for study: 18 years and older

Sponsors and collaborators: Hôpital Jean Minjoz

Contact: Sidney Chocron, MD, PhD

Phone: 33381668662

E-mail: sidney.chocron@univ-fcomte.fr

Back to Top | Article Outline
• Anemia •

NCT00436748

Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Subjects with Chronic Kidney Disease

Ages eligible for study: 1 year to 18 years

Sponsors and collaborators: Amgen

Contact: Amgen Call Center

Phone: 866-572-6436

NCT01235936

Safety and Efficacy Study for AKB-6548 in Subjects with Chronic Kidney Disease and Anemia

Ages eligible for study: 18 years to 79 years

Sponsors and collaborators: Akebia Therapeutics

Contact: Akebia Call Center

Phone: 855-252-6548

E-mail: AKB6548@akebia.com

NCT00838097

EU Registry in Pediatric CKD Patients Looking at Safety and Usage Patterns of Darbepoetin Alfa

Ages eligible for study: Up to 16 years

Sponsors and collaborators: Amgen

Contact: Amgen Call Center

Phone: 866-572-6436

NCT00925587

Study Evaluating Once-Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-Dialysis Patients with Chronic Kidney Disease

Ages eligible for study: 18 years and older

Sponsors and collaborators: Amgen

Contact: Amgen Call Center

Phone: 866-572-6436

Back to Top | Article Outline
• Autosomal Dominant Polycystic Kidney Disease •

NCT01223755

Sirolimus in Autosomal Dominant Polycystic Kidney Disease and Severe Renal Insufficiency

Ages eligible for study: 18 years to 80 years

Sponsors and collaborators: Mario Negri Institute for Pharmacological Research

Contact: Norberto Perico, MD

Phone: 0039 035 45351

E-mail: norberto.perico@marionegri.it

NCT00571909

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain Study

Ages eligible for study: 18 years and older

Sponsors and collaborators: Mayo Clinic

Contact: Marie C. Hogan, MD, PhD

Phone: 507-266-1963

E-mail: hogan.marie@mayo.edu

Back to Top | Article Outline
• Chronic Kidney Disease •

NCT01194154

A Study of Mircera in Patients with Chronic Kidney Disease (PRIMAVERA)

Ages eligible for study: 18 years and older

Sponsors and collaborators: Hoffmann-La Roche

Contact: Please reference Study

ID Number: ML22916

Phone: 888-662-6728

E-mail: genentechclinicaltrials@druginfo.com

NCT01120314

Pharmacokinetic, Pharmacodynamic, and Tolerability Study of Otamixaban in Patients with Severe Renal Impairment

Ages eligible for study: 18 years to 79 years

Sponsors and collaborators: Sanofi-Aventis

E-mail: Contact-Us@sanofi-aventis.com

NCT01237899

Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Effect on Renal Potassium Clearance

Ages eligible for study: 18 years to 65 years

Sponsors and collaborators: Eli Lilly and Company

Phone: 877-CTLILLY (877-285-4559)

NCT01232010

Clinical Study to Investigate the Safety and Pharmacokinetics of SK3530 Tablet in Renal-Impaired Male Patients

Ages eligible for study: 19 years to 64 years

Sponsors and collaborators: Asan Medical Center and SK Chemicals Co.

Contact: Kyun-Seop Bae, MD, PhD

Phone: 02-3010-4622

Back to Top | Article Outline
• Chronic Kidney Disease–Mineral and Bone Disorder •

NCT01214356

Impact of Vitamin D on Diabetic Kidney Disease in African-Americans

Ages eligible for study: 18 years and older

Sponsors and collaborators: Medical University of South Carolina

Contact: Vanessa A. Diaz, MD, MS

Phone: 843-792-7241

E-mail: diazva@musc.edu

Contact: Tara M. Hogue

Phone: 843-792-0800

E-mail: hoguetm@musc.edu

NCT00745719

Parathyroidectomy in End-Stage Renal Disease

Ages eligible for study: 18 years to 80 years

Sponsors and collaborators: University of Hong Kong

Contact: Angela Y. M. Wang, MD, PhD

Phone: 28554111, ext 4949

E-mail: aymwang@hku.hk

NCT00587158

Oral Paricalcitol in Kidney Transplant Recipients

Ages eligible for study: 18 years and older

Sponsors and collaborators: Mayo Clinic and Abbott

Contact: Rhette S. Lambert

Phone: 480-342-1335

E-mail: lambert.rhette@mayo.edu

Contact: Misty M. Berndt

Phone: 507-583-4071

E-mail: berndt.misty@mayo.edu

NCT00893451

Study of Vitamin D3 Supplementation in Patients with Chronic Kidney Disease

Ages eligible for study: 18 years and older

Sponsors and collaborators: Sahlgrenska University Hospital, Sweden

Contact: Hamid R. Dezfoolian, MD

Phone: 46704948377

E-mail: hamid.dezfoolian@vgregion.se

Contact: Maria Svensson, PhD

E-mail: maria.svensson@wlab.gu.se

NCT01003275

Metabolic Effects of Paricalcitol

Ages eligible for study: 18 years and older

Sponsors and collaborators: University of Washington and Abbott

Contact: Ian H. de Boer, MD, MS

Phone: 206-616-5403

E-mail: deboer@u.washington.edu

Back to Top | Article Outline
• Diabetes •

NCT01113801

A Study in Patients with Diabetic Kidney

Disease

Ages eligible for study: 25 years and older

Sponsors and collaborators: Eli Lilly and Company, and Collaborative Study Group

Contact: Eli Lilly and Company

Phone: 877-CTLILLY (877-285-4559)

NCT00175721

Trial Comparing Care in Multiple Clinics Versus Care in a Cardiac, Diabetes, and Kidney Care Clinic

Ages eligible for study: 18 years to 85 years

Sponsors and collaborators: University of British Columbia

Contact: Katy Vela

Phone: 604-682-2344, ext. 69460

E-mail: kvela@providencehealth.bc.ca

Contact: Sarah Noble

Phone: 604-682-2344, ext. 62510

E-mail: snoble@providencehealth.bc.ca

NCT01213212

Preventing Renal Functional Abnormalities with Calorie Restriction in Subjects with Abdominal Obesity and Type 2 Diabetes at Increased Renal and Cardiovascular Risk

Ages eligible for study: 40 years to 80 years

Sponsors and collaborators: Mario Negri Institute for Pharmacological Research and Istituto Superiore di Sanita

Contact: Piero Ruggenenti, MD

Phone: 003903545351

E-mail: piero.ruggenenti@marionegri.it

NCT01064414

An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients with Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Ages eligible for study: 25 years and older

Sponsors and collaborators: Johnson & Johnson Pharmaceutical Research & Development LLC

E-mail: info1@veritasmedicine.com

NCT01098539

A Study of the Efficacy and Safety of Albiglutide in Subjects with Type 2 Diabetes with Renal Impairment

Ages eligible for study: 18 years and older

Sponsors and collaborators: GlaxoSmithKline

Contact: US GSK Clinical Trials Call Center

Phone: 877-379-3718

NCT00938158

A Study of the Pharmacokinetics of Albiglutide in Normal and Renally-Impaired Subjects

Ages eligible for study: 30 years to 75 years

Sponsors and collaborators: GlaxoSmithKline

Contact: US GSK Clinical Trials Call Center

Phone: 877-379-3718

NCT01113801

A Study in Patients with Diabetic Kidney Disease

Ages eligible for study: 25 years and older

Sponsors and collaborators: Eli Lilly and Company, and Collaborative Study Group (CSG)

Phone: 877-CTLILLY (877-285-4559)

NCT01043029

A Study of Aleglitazar in Type 2 Diabetes Patients with Moderate Renal Impairment

Ages eligible for study: 18 years and older

Sponsors and collaborators: Hoffmann-La Roche

Contact: Please reference Study

ID Number: BC22419

Phone: 888-662-6728

E-mail: genentechclinicaltrials@druginfo.com

Back to Top | Article Outline
• Hemodialysis •

NCT01228123

Randomized Clinical Trial Comparing Continuous Versus Intermittent Hemodialysis in ICU Patients

Ages eligible for study: 18 years and older

Sponsors and collaborators: Charite University, Berlin

Contact: Prof. Dr. Achim Joerres

Phone: 49-30-450-665537

E-mail: achim.joerres@charite.de

Back to Top | Article Outline
• Immunosuppression •

NCT01132157

Comparison of the Protective Effect of Desflurane and Propofol in Patients with Renal Transplantation

Ages eligible for study: 20 years and older

Sponsors and collaborators: Yonsei University

Contact: Bon Nyeo Koo, MD, PhD

Phone: 82-2-2228-2422

E-mail: koobn@yuhs.ac

NCT00811915

Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney Transplantation

Ages eligible for study: 18 years to 76 years

Sponsors and collaborators: Rouen University Hospital

Contact: Caroline Freguin, MD

Phone: 0232889152

E-mail: caroline.freguin@chu-rouen.fr

NCT00895583

Study Evaluating a Planned Transition from Tacrolimus to Sirolimus in Kidney Transplant Recipients

Ages eligible for study: 18 years and older

Sponsors and collaborators: Wyeth

Contact: Pfizer CT.gov Call Center

Phone: 800-718-1021

NCT00502242

Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Renal Transplant Patients Converted to Sirolimus

Ages eligible for study: 18 years and older

Sponsors and collaborators: Wyeth

Contact: Pfizer CT.gov Call Center

Phone: 800-718-1021

NCT00933231

Comparison of Standard Versus Low-Dose Advagraf with or Without Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker on Histology and Function of Renal Allografts

Ages eligible for study: 18 years and older

Sponsors and collaborators: Astellas Pharma and Astellas Pharma Canada

Contact: Astellas Pharma Canada Medical Information

Phone: 888-338-1824

NCT00565331

Rituximab for Prevention of Rejection After Renal -Transplantation

Ages eligible for study: 18 years and older

Sponsors and collaborators: Radboud University, Hoffmann-La Roche, and Astellas Pharma GmbH

Contact: Luuk Hilbrands, MD

Phone: 312-431-4761

E-mail: l.hilbrands@nier.umcn.nl

NCT00752479

Mesenchymal Stem Cells Under Basiliximab/Low-Dose RATG to Induce Renal Transplant Tolerance

Ages eligible for study: 18 years to 80 years

Sponsors and collaborators: Mario Negri Institute for Pharmacological Research

Contact: Piero Ruggenenti, MD

Phone: 0039 035 269296

E-mail: pruggenenti@ospedaliriuniti.bergamo.it

NCT01154387

Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

Ages eligible for study: 18 years to 60 years

Sponsors and collaborators: Tolera Therapeutics

Contact: Leslie O'Toole, RN

Phone: 269-585-2100, ext. 2111

E-mail: lotoole@tolera.com

NCT01224860

Telmisartan Versus Losartan in Kidney Transplantation

Ages eligible for study: 18 years to 80 years

Sponsors and collaborators: Mario Negri Institute for Pharmacological Research

Contact: Paolo Cravedi, MD

Phone: 0039-035-45351

E-mail: paolo.cravedi@marionegri.it

NCT00758602

A Study of CellCept (Mycophenolate Mofetil) Combined with Tacrolimus and Corticosteroids in Kidney Transplant Patients

Ages eligible for study: Up to 75 years

Sponsors and collaborators: Hoffmann-La Roche

Contact: Please reference Study

ID Number: ML21740

Phone: 888-662-6728

E-mail: genentechclinicaltrials@druginfo.com

NCT01236287

Special Access for the Use of Voclosporin for Kidney Transplantation

Ages eligible for study: 18 years to 65 years

Sponsors and collaborators: Weill Cornell Medical College

Contact: Meredith J. Aull, PharmD

Phone: 212-746-5330

E-mail: mea9008@med.cornell.edu

NCT00782821

Randomized Trial of Induction Therapies in High-Immunological-Risk Kidney Transplant Recipients

Ages eligible for study: 18 years to 65 years

Sponsors and collaborators: University of Cincinnati, Millennium Pharmaceuticals, and Genzyme

Contact: Garth E. Wall

Phone: 513-558-0289

E-mail: garth.wall@uc.edu

Back to Top | Article Outline
• Transplantation •

NCT00975000

Treatment of Autonomous Hyperparathyroidism in Post-Renal-Transplant Recipients

Ages eligible for study: 18 years and older

Sponsors and collaborators: Amgen

Contact: Amgen Call Center

Phone: 866-572-6436

NCT00001858

Monitoring for Tolerance to Kidney or Combined Kidney- Pancreas Transplants

Sponsors and collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Contact: Patient Recruitment and Public Liaison Office

Phone: 800-411-1222

E-mail: prpl@mail.cc.nih.gov

NCT00592020

Short Transverse Versus Conventional Hockey Stick Incision in Kidney Transplantation

Ages eligible for study: 18 years and older

Sponsors and collaborators: University Hospital Inselspital, Berne, Switzerland

Contact: Daniel Inderbitzin, MD

Phone: 0041316322111

E-mail: daniel.inderbitzin@insel.ch

© 2011 Lippincott Williams & Wilkins, Inc.

Login